Market Overview

After Recent Run, Penumbra Downgraded On Fears Its Upside Is Exhausted

Share:
After Recent Run, Penumbra Downgraded On Fears Its Upside Is Exhausted
Related PEN
7 Biggest Price Target Changes For Tuesday
Benzinga's Top Upgrades, Downgrades For October 8, 2018
These Two Leading Stocks Trigger Sell Signals, Just Days After Breakouts (Investor's Business Daily)

The medical device company Penumbra Inc (NYSE: PEN) issued a consensus-beating earnings report Nov. 7. 

The Analyst

BMO Capital Markets' Joanne Wuensch downgraded Penumbra from Outperform to Market Perform and reduced the price target from $117 to $110.

The Thesis

The analyst said she still likes the stock in the long term, but it currently trades with a premium to its peers. (See Wuensch's track record here.) 

Penumbra trades at 8.2 times 2018 EV/revenue and it has a growth rate of 20 percent, while its peers trade at 6.5 times with 25 percent growth, the analyst said.

The stock has historically traded at five to eight times EV/Revenue and nearly reached 10x for two months in the fourth quarter of 2017, according to BMO. 

Upside potential for the estimates exists, but the estimate beats have slowed, Wuensch said. The analyst said she expects Penumbra to expand its pipeline beyond a neurovascular and peripheral vascular strategy, and saidthe company is going to continue to benefit from an underpenetrated ischemic stroke market. Although Penumbra has much long-term potential, the risk-reward over the next 12 months is not as compelling, Wuensch said. 

The Price Action

The stock dropped more than 5 percent Tuesday, and it's trading almost 20 percent below its 52-week high, which it hit after the earnings report in November.

Latest Ratings for PEN

DateFirmActionFromTo
Nov 2018BMO CapitalMaintainsMarket PerformMarket Perform
Oct 2018RBC CapitalInitiates Coverage OnOutperform
Aug 2018BMO CapitalMaintainsMarket PerformMarket Perform

View More Analyst Ratings for PEN
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Joanne WuenschAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (PEN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMTDMorgan StanleyUpgrades65.0
APOMorgan StanleyDowngrades34.0
ARMKBairdUpgrades44.0
CGMorgan StanleyDowngrades23.0
EIXEdward JonesDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Can Semiconductors Get Their Groove Back In 2018? Here's Oppenheimer's Playbook

UBS Loses Conviction In Spark Therapeutics, Downgrades